Role of (18)F-choline PET/CT in Evaluation of Patients with Prostate Carcinoma

Overview

Journal Radiol Oncol

Publisher Sciendo

Specialties Oncology
Radiology

Date 2012 Aug 31

PMID 22933929

Citations 18

Authors

Marina Hodolic

Affiliations

Soon will be listed here.

Abstract

Background: Choline presents a high affinity for malignant prostate tissue. It can be labelled with positron emitting (18)F, and used for the evaluation of patients with prostate carcinoma by PET/CT imaging. The aim of this paper is to summarise our experience with fluoromethylcholine ((18)F-choline) PET/CT in patients with prostate cancer.

Methods: In 4 months we investigated the patients with histopathological (or cytological) confirmed prostate cancer. Two observers evaluated the early and late (18)F-choline PET images in correlation with corresponding localising CT images and using the semiquantitative standard uptake value (SUV) calculation.

Results: The (18)F-choline PET/CT was made in 50 patients with prostate cancer. There were 18 patients after radical prostatectomy and 32 without surgery. In all patients without surgery the pathological uptake was seen in the prostate. In 14 (44 %) patients of this group there was evidence of metastatic spread in local or distant lymph nodes and/or bones. In out of 18 patients after radical prostatectomy the local recurrence was detected in 6 patients (33%) and distant metastases were present in 2 patients (10%).

Conclusions: (18)F-choline PET/CT seems to be useful imaging modality in patients with prostate carcinoma; it can demonstrate spread of the disease preoperatively and detect the local recurrence after radical prostatectomy.

Citing Articles

Comparison of Ga-68 PSMA PET/CT and Multiparametric MRI for Initial Detection and Staging of Prostate Cancer.

Gauthaman D, Luthra K, Lele V World J Nucl Med. 2024; 23(2):79-87.

PMID: 38933063 PMC: 11199037. DOI: 10.1055/s-0044-1779749.

Unveiling the best predictive models for early‑onset metastatic cancer: Insights and innovations (Review).

Yu L, Huang Z, Xiao Z, Tang X, Zeng Z, Tang X Oncol Rep. 2024; 51(4).

PMID: 38456540 PMC: 10940877. DOI: 10.3892/or.2024.8719.

Hyperfunctioning parathyroid gland and skeletal involvement on [F]fluorocholine PET/CT: one look with two views.

Nappi C, Piscopo L, Klain M, Mainolfi C, Vergara E, Adamo D Eur J Hybrid Imaging. 2022; 6(1):28.

PMID: 36504377 PMC: 9742067. DOI: 10.1186/s41824-022-00149-y.

PET Oncological Radiopharmaceuticals: Current Status and Perspectives.

Lin M, Coll R, Cohen A, Georgiou D, Manning H Molecules. 2022; 27(20).

PMID: 36296381 PMC: 9609795. DOI: 10.3390/molecules27206790.

Diagnostic accuracy of F-18-Fluorocholine PET/CT and multiparametric MRI for prostate cancer.

Kim J, Song Y, Lee W, Lee H, Hwang S, Hong S Prostate Int. 2022; 10(3):152-157.

PMID: 36225289 PMC: 9520420. DOI: 10.1016/j.prnil.2022.04.003.

References

Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W . Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008; 35(10):1766-74. DOI: 10.1007/s00259-008-0788-z. View

Reske S . [Nuclear imaging of prostate cancer: current status]. Urologe A. 2007; 46(11):1485-99. DOI: 10.1007/s00120-007-1572-6. View

Yamamoto Y, Nishiyama Y, Kameyama R, Okano K, Kashiwagi H, Deguchi A . Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med. 2008; 49(8):1245-8. DOI: 10.2967/jnumed.108.052639. View

Talbot J, Gutman F, Huchet V, Kerrou K, Balogova S, Kerrouche N . [Clinical usefulness of positron emission tomography in prostate cancer]. Presse Med. 2007; 36(12 Pt 2):1794-806. DOI: 10.1016/j.lpm.2007.02.030. View

Schillaci O, Calabria F, Tavolozza M, Ciccio C, Carlani M, Caracciolo C . 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl Med Commun. 2009; 31(1):39-45. DOI: 10.1097/mnm.0b013e328330adc5. View

Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A . Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med. 2008; 113(6):895-904. DOI: 10.1007/s11547-008-0263-8. View

Watanabe H, Kanematsu M, Kondo H, Kako N, Yamamoto N, Yamada T . Preoperative detection of prostate cancer: a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging. J Magn Reson Imaging. 2010; 31(5):1151-6. DOI: 10.1002/jmri.22157. View

Steiner C, Vees H, Zaidi H, Wissmeyer M, Berrebi O, Kossovsky M . Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence. Nuklearmedizin. 2009; 48(1):1-9. DOI: 10.3413/nukmed-0194. View

Kwee S, Wei H, Sesterhenn I, Yun D, Coel M . Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med. 2006; 47(2):262-9. View

10.

Le C, van de Weijer E, Pos F, Vogel W . Active inflammation in 18F-methylcholine PET/CT. Eur J Nucl Med Mol Imaging. 2009; 37(3):654-5. PMC: 2822228. DOI: 10.1007/s00259-009-1329-0. View

11.

Naji M, Hodolic M, El-Refai S, Khan S, Marzola M, Rubello D . Endocrine tumors: the evolving role of positron emission tomography in diagnosis and management. J Endocrinol Invest. 2009; 33(1):54-60. DOI: 10.1007/BF03346550. View

12.

Langsteger W, Heinisch M, Fogelman I . The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med. 2005; 36(1):73-92. DOI: 10.1053/j.semnuclmed.2005.09.002. View

13.

Igerc I, Kohlfurst S, Gallowitsch H, Matschnig S, Kresnik E, Gomez-Segovia I . The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur J Nucl Med Mol Imaging. 2008; 35(5):976-83. DOI: 10.1007/s00259-007-0686-9. View

14.

Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T . [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging. 2006; 33(12):1387-98. DOI: 10.1007/s00259-006-0150-2. View

15.

Reske S, Blumstein N, Glatting G . [PET and PET/CT in relapsing prostate carcinoma]. Urologe A. 2006; 45(10):1240, 1242-4, 1246-8, 1250. DOI: 10.1007/s00120-006-1212-6. View

16.

Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F . 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010; 254(3):925-33. DOI: 10.1148/radiol.09090413. View